These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 7578526)

  • 21. How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types.
    Favaloro EJ; Mohammed S; Vong R; Oliver S; Brennan Y; Favaloro JW; Curnow J
    Haemophilia; 2021 Jan; 27(1):137-148. PubMed ID: 33215808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor.
    Mannucci PM; Lombardi R; Bader R; Vianello L; Federici AB; Solinas S; Mazzucconi MG; Mariani G
    Blood; 1985 Oct; 66(4):796-802. PubMed ID: 3876122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease.
    Casonato A; Pontara E; Sartorello F; Cattini MG; Sartori MT; Padrini R; Girolami A
    Blood; 2002 Jan; 99(1):180-4. PubMed ID: 11756169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unique multimeric pattern of von Willebrand factor in a patient with a benign monoclonal gammopathy.
    López-Fernández MF; López-Berges C; Martín R; Nieto J; del Rio F; López-Borrasca A; Batlle J
    Scand J Haematol; 1986 Mar; 36(3):302-8. PubMed ID: 3486452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia.
    Casonato A; Gallinaro L; Cattini MG; Pontara E; Padrini R; Bertomoro A; Daidone V; Pagnan A
    Haematologica; 2010 Aug; 95(8):1366-72. PubMed ID: 20305138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation.
    Casonato A; Steffan A; Pontara E; Zucchetto A; Rossi C; De Marco L; Girolami A
    Thromb Haemost; 1999 Feb; 81(2):224-8. PubMed ID: 10063996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization.
    Casonato A; Pontara E; Sartorello F; Bertomoro A; Durante C; Girolami A
    J Lab Clin Med; 2001 Jan; 137(1):70-6. PubMed ID: 11150026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to desmopressin in type IID von Willebrand's disease.
    Thomas N; O'Callaghan U; Lowe GD; Olszynski V; Kernoff PB; Abildgaard CF; Tuddenham EG
    Clin Lab Haematol; 1989; 11(3):189-97. PubMed ID: 2591151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function.
    Casonato A; Cattini MG; Soldera C; Marcato S; Sartorello F; Pontara E; Pagnan A
    J Lab Clin Med; 2004 Nov; 144(5):254-9. PubMed ID: 15570243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discrepant increase in factor VIII: C and von Willebrand factor after DDAVP infusion in a patient with variant von Willebrand's disease.
    Casonato A; Sartori MT; Pontara E; Bertomoro A; Dannhäuser D; Girolami
    Blood Coagul Fibrinolysis; 1991 Aug; 2(4):567-73. PubMed ID: 1768767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
    Cattaneo M; Simoni L; Gringeri A; Mannucci PM
    Br J Haematol; 1994 Feb; 86(2):333-7. PubMed ID: 8199023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications.
    Pérez-Rodríguez A; García-Rivero A; Lourés E; López-Fernández MF; Rodríguez-Trillo A; Batlle J
    Haematologica; 2009 May; 94(5):679-86. PubMed ID: 19286880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteolytic processing of von Willebrand factor subunit: heterogeneity in type-IIA von Willebrand disease.
    Batlle J; Lasierra J; Villamor AF; Navarro JL; Pardo A; Campos M; Justiça B; López Fernández MF
    Ann Hematol; 1994 Mar; 68(3):111-5. PubMed ID: 8167176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza.
    Gézsi A; Budde U; Deák I; Nagy E; Mohl A; Schlammadinger A; Boda Z; Masszi T; Sadler JE; Bodó I
    J Thromb Haemost; 2010 Jun; 8(6):1273-80. PubMed ID: 20088930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired type II von Willebrand's disease: demonstration of a complexed inhibitor of the von Willebrand factor-platelet interaction and response to treatment.
    Goudemand J; Samor B; Caron C; Jude B; Gosset D; Mazurier C
    Br J Haematol; 1988 Feb; 68(2):227-33. PubMed ID: 3126793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DDAVP in type IIa von Willebrand's disease.
    Gralnick HR; Williams SB; McKeown LP; Rick ME; Maisonneuve P; Jenneau C; Sultan Y
    Blood; 1986 Feb; 67(2):465-8. PubMed ID: 3080040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-resolution analysis of von Willebrand factor multimeric composition defines a new variant of type I von Willebrand disease with aberrant structure but presence of all size multimers (type IC).
    Ciavarella G; Ciavarella N; Antoncecchi S; De Mattia D; Ranieri P; Dent J; Zimmerman TS; Ruggeri ZM
    Blood; 1985 Dec; 66(6):1423-9. PubMed ID: 3877533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantification and facilitated comparison of von Willebrand factor multimer patterns by densitometry.
    Studt JD; Budde U; Schneppenheim R; Eisert R; von Depka Prondzinski M; Ganser A; Barthels M
    Am J Clin Pathol; 2001 Oct; 116(4):567-74. PubMed ID: 11601142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Higher and lower active circulating VWF levels: different facets of von Willebrand disease.
    Casonato A; Pontara E; Morpurgo M; Sartorello F; De Groot PG; Cattini MG; Daidone V; De Marco L
    Br J Haematol; 2015 Dec; 171(5):845-53. PubMed ID: 26456374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand's disease with low platelet von Willebrand factor content.
    Casonato A; Sartori MT; Pontara E; Zucchetto A; Dannhäuser D; Patrassi G; Girolami A
    Blood Coagul Fibrinolysis; 1992 Apr; 3(2):149-53. PubMed ID: 1606286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.